AVAVA

AVAVA is a pioneer in the aesthetic medical devices space, committed to prioritizing patient needs and delivering impactful clinical results for individuals of all skin types worldwide. The company's flagship product, MIRIA™, has received FDA Clearance 510(k), showcasing the firm's dedication to innovation and safety in the industry. With its patented Focal Point Technology™ and AVAVASite high-resolution imaging system, AVAVA offers precise, non-invasive treatments with actionable data, setting a new standard for patient care and provider experience.

AVAVA's MIRIA System stands out as a high-energy focused intradermal laser, designed to target specific depths in the skin while minimizing damage to the epidermis, making it especially suitable for patients with darker skin tones. Extensive clinical studies have demonstrated its efficacy in addressing various skin aging signs, including wrinkles, sun damage, and acne scarring, across diverse skin types and colors. Additionally, the system's advanced technology ensures patient comfort and minimal downtime, enhancing the overall treatment experience.

By catering to the needs of over 11.7 million US-individuals seeking facial rejuvenation annually, AVAVA is positioned to have a significant impact on the aesthetic medical device market. With a limited release of MIRIA™ scheduled for 2023 and widespread commercial availability in 2024, the company is poised to expand its reach and deliver meaningful, inclusive solutions to a global audience. Based in the United States, AVAVA is a promising venture for investors looking to support groundbreaking advancements in the aesthetics and healthcare sectors.